Haemacure has developed and patented a unique process to extract fibrinogen and thrombin from human plasma, resulting in its human fibrin sealant product.

Haemacure's patented extraction technology allows a more gentle separation and purification of proteins than the traditional Cohn fractionation process, thereby producing a higher quality fibrin sealant.  Haemacure's technology also delivers much higher fibrinogen production yields.  The Cohn process is very harsh to, has a shearing effect on, and may cause a substantial amount of denaturalization of proteins.

Haemacure's unique and proprietary extraction technology provides a superior product in terms of use, clot performance and reconstitution time.